3.40
Schlusskurs vom Vortag:
$3.36
Offen:
$3.4
24-Stunden-Volumen:
395.41K
Relative Volume:
1.15
Marktkapitalisierung:
$168.74M
Einnahmen:
$230.47M
Nettoeinkommen (Verlust:
$30.28M
KGV:
5.5738
EPS:
0.61
Netto-Cashflow:
$38.86M
1W Leistung:
+0.29%
1M Leistung:
+0.00%
6M Leistung:
+14.48%
1J Leistung:
-8.11%
Puma Biotechnology Inc Stock (PBYI) Company Profile
Firmenname
Puma Biotechnology Inc
Sektor
Branche
Telefon
(424) 248-6500
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Vergleichen Sie PBYI mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PBYI
Puma Biotechnology Inc
|
3.40 | 168.27M | 230.47M | 30.28M | 38.86M | 0.61 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2021-09-28 | Hochstufung | Citigroup | Neutral → Buy |
2020-06-25 | Fortgesetzt | BofA/Merrill | Underperform |
2019-10-08 | Herabstufung | Goldman | Neutral → Sell |
2019-05-10 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2019-05-10 | Herabstufung | Citigroup | Buy → Neutral |
2019-01-17 | Eingeleitet | Leerink Partners | Mkt Perform |
2019-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
2018-11-19 | Hochstufung | Goldman | Sell → Neutral |
2018-11-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
2018-11-02 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-09-17 | Eingeleitet | Goldman | Sell |
2018-05-11 | Bestätigt | Stifel | Buy |
2017-11-10 | Bestätigt | Citigroup | Buy |
2017-11-10 | Bestätigt | RBC Capital Mkts | Sector Perform |
2017-10-02 | Bestätigt | Stifel | Buy |
2017-09-11 | Bestätigt | Credit Suisse | Outperform |
2017-07-10 | Fortgesetzt | Leerink Partners | Outperform |
2017-06-06 | Bestätigt | RBC Capital Mkts | Sector Perform |
2017-05-25 | Bestätigt | RBC Capital Mkts | Sector Perform |
2017-03-02 | Bestätigt | RBC Capital Mkts | Sector Perform |
Alle ansehen
Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten
Is Puma Biotechnology Inc. a good long term investmentSkyrocketing returns - Jammu Links News
What drives Puma Biotechnology Inc. stock priceSignificant capital appreciation - Autocar Professional
Puma Biotechnology Inc. Stock Analysis and ForecastMassive profits - Autocar Professional
Does Puma Biotechnology Inc. stock pay reliable dividendsFree Access to Community - Newser
What analysts say about Puma Biotechnology Inc. stockTremendous gains - Jammu Links News
how puma biotechnology inc. stock performs during market volatilityFree Stock Selection - Newser
How Puma Biotechnology Inc. stock performs during market volatilityFree Stock Selection with 300% Return - Newser
Why Puma Biotechnology Inc. stock attracts strong analyst attentionStrong Buy Recommendations - Newser
What makes Puma Biotechnology Inc. stock price move sharplySteady Income Ideas - Newser
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? - Yahoo Finance
Puma biotechnology CFO Nougues sells $33649 in stock By Investing.com - Investing.com South Africa
Puma biotechnology CFO Nougues sells $33649 in stock - Investing.com Australia
Puma biotechnology SVP Hunt sells $27624 in stock By Investing.com - Investing.com South Africa
Puma biotechnology SVP Hunt sells $27624 in stock - Investing.com Australia
Puma Biotechnology Executives Sell Shares Amid Ongoing Company Challenges - AInvest
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors - Yahoo Finance
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Puma Biotechnology, Inc.(NasdaqGS: PBYI) dropped from Russell 2000 Growth Index - MarketScreener
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? - Yahoo Finance
Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment (NASDAQ:PBYI) - Seeking Alpha
Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain - Nasdaq
Puma Biotechnology Updates Bylaws for Compliance - TipRanks
Puma Biotechnology Holds Annual Stockholders Meeting 2025 - TipRanks
Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance
With 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backing - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Sold by Squarepoint Ops LLC - Defense World
78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial Corp - Defense World
Puma Biotechnology Awards Key Talent with 18,250 RSUs in Strategic Retention Move - Stock Titan
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st
Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Puma Biotechnology Inc-Aktie (PBYI) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
NOUGUES MAXIMO F | Chief Financial Officer |
Jul 08 '25 |
Sale |
3.53 |
5,587 |
19,739 |
208,164 |
NOUGUES MAXIMO F | Chief Financial Officer |
Jul 09 '25 |
Sale |
3.54 |
3,935 |
13,910 |
204,229 |
HUNT DOUGLAS M | See Remarks |
Jul 08 '25 |
Sale |
3.53 |
4,374 |
15,453 |
168,337 |
HUNT DOUGLAS M | See Remarks |
Jul 09 '25 |
Sale |
3.54 |
3,443 |
12,171 |
164,894 |
AUERBACH ALAN H | President and CEO |
Jul 08 '25 |
Sale |
3.53 |
25,592 |
90,417 |
7,202,481 |
AUERBACH ALAN H | President and CEO |
Jul 09 '25 |
Sale |
3.54 |
21,580 |
76,285 |
7,180,901 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):